Dnaprint Genomics Stock Beta

DNAPrint Genomics fundamentals help investors to digest information that contributes to DNAPrint Genomics' financial success or failures. It also enables traders to predict the movement of DNAPrint Stock. The fundamental analysis module provides a way to measure DNAPrint Genomics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to DNAPrint Genomics stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

DNAPrint Genomics Company Beta Analysis

DNAPrint Genomics' Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.

Beta

 = 

Covariance

Variance

More About Beta | All Equity Analysis

Current DNAPrint Genomics Beta

    
  23.48  
Most of DNAPrint Genomics' fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, DNAPrint Genomics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
Competition

In accordance with the recently published financial statements, DNAPrint Genomics has a Beta of 23.483. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The beta for all United States stocks is notably lower than that of the firm.

DNAPrint Beta Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses DNAPrint Genomics' direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of DNAPrint Genomics could also be used in its relative valuation, which is a method of valuing DNAPrint Genomics by comparing valuation metrics of similar companies.
DNAPrint Genomics is currently under evaluation in beta category among its peers.
As the market goes up, the company is expected to outperform it. However, if the market returns are negative, DNAPrint Genomics will likely underperform.

DNAPrint Fundamentals

Currently Active Assets on Macroaxis

Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.

Other Consideration for investing in DNAPrint Stock

If you are still planning to invest in DNAPrint Genomics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the DNAPrint Genomics' history and understand the potential risks before investing.
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.